Immix Biopharma (NASDAQ:IMMX) Price Target Raised to $15.00

Immix Biopharma (NASDAQ:IMMX) had its target price lifted by HC Wainwright from $12.00 to $15.00 in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Morgan Stanley started coverage on shares of Immix Biopharma in a research report on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price objective for the company. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Mizuho initiated coverage on shares of Immix Biopharma in a report on Monday, February 9th. They issued an “outperform” rating and a $14.00 target price on the stock. Finally, Citizens Jmp began coverage on shares of Immix Biopharma in a report on Monday, March 9th. They issued an “outperform” rating and a $23.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock opened at $8.15 on Friday. The firm has a market cap of $431.71 million, a PE ratio of -9.16 and a beta of 0.25. The stock has a 50 day moving average of $7.77 and a 200 day moving average of $5.28. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.12). As a group, equities research analysts forecast that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in shares of Immix Biopharma in the 4th quarter worth about $20,471,000. Eventide Asset Management LLC bought a new position in Immix Biopharma during the 4th quarter valued at about $13,331,000. Marshall Wace LLP grew its holdings in Immix Biopharma by 3,495.4% during the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Millennium Management LLC purchased a new stake in Immix Biopharma in the 4th quarter worth about $8,681,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Immix Biopharma in the fourth quarter worth about $7,845,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.